Clinical Trial Update: Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ruxolitinib in previously treated idiopathic multicentric Castleman disease; recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castleman Disease
• Idiopathic Multicentric Castleman Disease

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University of Pennsylvania | Conditions: Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease | Phase 2 | Status: RECRUITING